|
[1]
|
Chintakuntlawar, A.V., et al. (2019) Diagnosis and Management of Anaplastic Thyroid Cancer. Endocrinology and Metabolism Clinics of North America, 48, 269-284. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Ranganath, R., Shah, M.A. and Shah, A.R. (2015) Anaplastic Thyroid Cancer. Current Opinion in Endocrinology & Diabetes and Obesity, 22, 387-391. [Google Scholar] [CrossRef]
|
|
[3]
|
Di Desidero, T., et al. (2020) Pharmacological Effects of Vinorelbine in Combination with Lenvatinib in Anaplastic Thyroid Cancer. Pharmacological Research, 158, Article ID: 104920. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Maniakas, A., et al. (2020) Evaluation of Overall Survival in Patients with Anaplastic Thyroid Carcinoma, 2000-2019. JAMA Oncology, 6, 1397-1404. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Kim, M., et al. (2021) Real-World Experience of Lenvatinib in Patients with Advanced Anaplastic Thyroid Cancer. Endocrine, 71, 427-433. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Wirth, L.J., et al. (2021) Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients with Anaplastic Thyroid Cancer. Journal of Clinical Oncology, 39, 2359-2366. [Google Scholar] [CrossRef]
|
|
[7]
|
Ito, Y., et al. (2017) Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma. Thyroid, 27, 1142-1148. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Chen, G., et al. (2015) Synergistic Anti-Proliferative Effect of Metformin and Sorafenib on Growth of Anaplastic Thyroid Cancer Cells and Their Stem Cells. Oncology Reports, 33, 1994-2000. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Kim, S.Y., et al. (2020) Synergistic Anticancer Activity of Sorafenib, Paclitaxel, and Radiation Therapy on Anaplastic thyroid Cancer in Vitro and in Vivo. Head & Neck, 42, 3678-3684. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Isham, C.R., et al. (2013) Pazopanib Enhances Paclitaxel-Induced Mitotic Catastrophe in Anaplastic Thyroid Cancer. Science Translational Medicine, 5, 166ra3. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Bible, K.C., et al. (2012) A Multiinstitutional Phase 2 Trial of Pazopanib Monotherapy in Advanced Anaplastic Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism, 97, 3179-3184. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Di Desidero, T., et al. (2019) Effects of Pazopanib Monotherapy vs. Pazopanib and Topotecan Combination on Anaplastic Thyroid Cancer Cells. Frontiers in Oncology, 9, Article No. 1202. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Kurebayashi, J., et al. (2006) Additive Antitumor Effects of Gefitinib and Imatinib on Anaplastic Thyroid Cancer Cells. Cancer Chemotherapy and Pharmacology, 58, 460-470. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Ha, H.T., et al. (2010) A Phase II Study of Imatinib in Patients with Advanced Anaplastic Thyroid Cancer. Thyroid, 20, 975-980. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Kim, E., et al. (2012) Imatinib Enhances Docetaxel-Induced Apoptosis through Inhibition of Nuclear Factor-κB Activation in Anaplastic Thyroid Carcinoma Cells. Thyroid, 22, 717-724. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Gui, L., et al. (2021) A Remarkable and Durable Response to Sintilimab and Anlotinib in the First-Line Treatment of an Anaplastic Thyroid Carcinoma without Targetable Genomic Alterations: A Case Report. OncoTargets and Therapy, 14, 2741-2746. [Google Scholar] [CrossRef]
|
|
[17]
|
D’Agostino, M., et al. (2012) Sunitinib Exerts Only Limited Effects on the Proliferation and Differentiation of Anaplastic Thyroid Cancer Cells. Thyroid, 22, 138-144. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Subbiah, V., et al. (2018) Dabrafenib and Trametinib Treatment in Patients with Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. Journal of Clinical Oncology, 36, 7-13. [Google Scholar] [CrossRef]
|
|
[19]
|
Liao, Y., et al. (2020) Melatonin Synergizes BRAF-Targeting Agent Dabrafenib for the Treatment of Anaplastic Thyroid Cancer by Inhibiting AKT/hTERT Signalling. Journal of Cellular and Molecular Medicine, 24, 12119-12130. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Smulever, A., et al. (2020) Re: “Complete Surgical Resection Following Neoadjuvant Dabrafenib plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma”. Thyroid, 30, 1224-1225. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Marten, K.A. and Gudena, V.K. (2015) Use of Vemurafenib in Anaplastic Thyroid Carcinoma: A Case Report. Cancer Biology & Therapy, 16, 1430-1433. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Prager, G.W., et al. (2016) Sustained Response to Vemurafenib in a BRAF V600E-Mutated Anaplastic Thyroid Carcinoma Patient. Thyroid (New York, N.Y.), 26, 1515-1516. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Harris, E.J., et al. (2019) Everolimus in Anaplastic Thyroid Cancer: A Case Series. Frontiers in Oncology, 9, Article No. 106. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Wagle, N., et al. (2014) Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer. The New England Journal of Medicine, 371, 1426-1433. [Google Scholar] [CrossRef]
|
|
[25]
|
Wunderlich, A., et al. (2012) Combined Inhibition of Cellular Pathways as a Future Therapeutic Option in Fatal Anaplastic Thyroid Cancer. Endocrine, 42, 637-646. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Mehta, A., et al. (2015) Carfilzomib Is an Effective Anticancer Agent in Anaplastic Thyroid Cancer. Endocrine-Related Cancer, 22, 319-329. [Google Scholar] [CrossRef]
|
|
[27]
|
Lin, S., et al. (2017) A Cyclin-Dependent Kinase Inhibitor, Dinaciclib in Preclinical Treatment Models of Thyroid Cancer. PLoS ONE, 12, e0172315. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Smallridge, R.C., et al. (2013) Efatutazone, an Oral PPAR-γ Agonist, in Combination with Paclitaxel in Anaplastic Thyroid Cancer: Results of a Multicenter Phase 1 Trial. The Journal of Clinical Endocrinology & Metabolism, 98, 2392-2400. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Granata, R., Locati, L.D. and Licitra, L. (2014) Fosbretabulin for the Treatment of Anaplastic Thyroid Cancer. Future Oncology, 10, 2015-2021. [Google Scholar] [CrossRef] [PubMed]
|